Clinical Laboratory Improvement Advisory Committee, 18244 [2015-07639]
Download as PDF
<![CDATA[
18244
Federal Register / Vol. 80, No. 64 / Friday, April 3, 2015 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2014–N–2187]
Identifying Potential Biomarkers for
Qualification and Describing Contexts
of Use To Address Areas Important to
Drug Development; Extension of
Comment Period
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice; extension of comment
period.
The Food and Drug
Administration (FDA) is extending the
comment period for the notice entitled
‘‘Identifying Potential Biomarkers for
Qualification and Describing Contexts of
Use to Address Areas Important to Drug
Development; Request for Comments’’
that appeared in the Federal Register of
February 13, 2015 (80 FR 8089). In the
notice, FDA requested comments on
identifying potential biomarkers for
qualification and describing contexts of
use to address areas important to drug
development. The Agency is taking this
action for an extension to allow
interested persons additional time to
submit comments.
DATES: Submit either electronic or
written comments by May 15, 2015
ADDRESSES: Submit electronic
comments to https://
www.regulations.gov. Submit written
comments to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, Rm.
1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT:
Marianne Noone, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 21, Rm. 4528,
Silver Spring, MD 20993–0002, 301–
796–7495.
SUMMARY:
SUPPLEMENTARY INFORMATION:
asabaliauskas on DSK5VPTVN1PROD with NOTICES
I. Background
In the Federal Register of February
13, 2015 (80 FR 8089), FDA published
a notice with a 60-day comment period
to request comments on identifying
potential biomarkers for qualification
and describing contexts of use to
address areas important to drug
development. FDA is encouraging
interested groups and individuals to
submit information on specific medical
and biological areas where novel
biomarkers can be identified that would
VerDate Sep<11>2014
18:48 Apr 02, 2015
Jkt 235001
meaningfully advance drug
development.
The current 60-day comment period
does not allow sufficient time to obtain
the broad public response that will
inform FDA’s Biomarker Qualification
Program going forward. FDA is
extending the comment period for an
additional 30 days, thus extending the
comment period to May 15, 2015. The
Agency believes that a 30-day extension
allows adequate time for interested
persons to submit comments without
significantly delaying progress on these
important issues.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Catherine Ramadei,
Acting Director, Management Analysis and
Services Office, Centers for Disease Control
and Prevention.
[FR Doc. 2015–07639 Filed 4–2–15; 8:45 am]
BILLING CODE 4163–18–P
II. Request for Comments
Interested persons may submit either
electronic comments regarding this
document to https://www.regulations.gov
or written comments to the Division of
Dockets Management (see ADDRESSES). It
is only necessary to send one set of
comments. Identify comments with the
docket number found in brackets in the
heading of this document. Received
comments may be seen in the Division
of Dockets Management between 9 a.m.
and 4 p.m., Monday through Friday, and
will be posted to the docket at https://
www.regulations.gov.
Dated: March 30, 2015.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2015–07631 Filed 4–2–15; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Clinical Laboratory Improvement
Advisory Committee
Correction: This notice was published
in the Federal Register on March 24,
2015, Volume 80, Number 56, Pages
15621–15622. The times and dates
should read as follows:
Times and Dates: 12:30 p.m.—5:00
p.m., April 15, 2015; 8:30 a.m.—12:00
p.m., April 16, 2015.
CONTACT PERSON FOR ADDITIONAL
INFORMATION: Nancy Anderson, Chief,
Laboratory Practice Standards Branch,
Division of Laboratory Programs,
Standards, and Services, Center for
Surveillance, Epidemiology and
Laboratory Services, Office of Public
Health Scientific Services, CDC, 1600
Clifton Road NE., Mailstop F–11,
Atlanta, Georgia 30329–4018; telephone
(404) 498–2741; or via email at
NAnderson@cdc.gov
PO 00000
Frm 00057
Fmt 4703
Sfmt 4703
DEPARTMENT OF HOMELAND
SECURITY
United States Immigration and
Customs Enforcement
Agency Information Collection
Activities: Extension, With Change, of
an Existing Information Collection;
Comment Request
60-Day Notice of Information
collection for review; I–312/I–312A;
Designation of Attorney in Fact/
Revocation of Attorney In Fact; OMB
Control No. 1653–0041.
ACTION:
The Department of Homeland
Security, U.S. Immigration and Customs
Enforcement (ICE), is submitting the
following information collection request
for review and clearance in accordance
with the Paperwork Reduction Act of
1995. The information collection is
published in the Federal Register to
obtain comments from the public and
affected agencies. Comments are
encouraged and will be accepted for
sixty days until June 2, 2015.
Written comments and suggestions
regarding items contained in this notice
and especially with regard to the
estimated public burden and associated
response time should be directed to the
Department of Homeland Security
(DHS), Scott Elmore, Forms
Management Office, U.S. Immigration
and Customs Enforcement, 801 I Street
NW., Mailstop 5800, Washington, DC
20536–5800.
Written comments and suggestions
from the public and affected agencies
concerning the proposed collection of
information should address one or more
of the following four points:
(1) Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
E:\FR\FM\03APN1.SGM
03APN1
]]>Agencies
[Federal Register Volume 80, Number 64 (Friday, April 3, 2015)]
[Notices]
[Page 18244]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2015-07639]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Clinical Laboratory Improvement Advisory Committee
Correction: This notice was published in the Federal Register on
March 24, 2015, Volume 80, Number 56, Pages 15621-15622. The times and
dates should read as follows:
Times and Dates: 12:30 p.m.--5:00 p.m., April 15, 2015; 8:30 a.m.--
12:00 p.m., April 16, 2015.
Contact Person for Additional Information: Nancy Anderson, Chief,
Laboratory Practice Standards Branch, Division of Laboratory Programs,
Standards, and Services, Center for Surveillance, Epidemiology and
Laboratory Services, Office of Public Health Scientific Services, CDC,
1600 Clifton Road NE., Mailstop F-11, Atlanta, Georgia 30329-4018;
telephone (404) 498-2741; or via email at NAnderson@cdc.gov
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining to
announcements of meetings and other committee management activities for
both the Centers for Disease Control and Prevention and the Agency for
Toxic Substances and Disease Registry.
Catherine Ramadei,
Acting Director, Management Analysis and Services Office, Centers for
Disease Control and Prevention.
[FR Doc. 2015-07639 Filed 4-2-15; 8:45 am]
BILLING CODE 4163-18-P
